Grifols market cap is €10.9 b, and annual revenue was $5.34 b in FY 2020

Grifols Gross profit (FY, 2020)2.3 B

Grifols Gross profit margin (FY, 2020), %42.2%

Grifols Net income (FY, 2020)709 M

Grifols EBIT (FY, 2020)996.1 M

Grifols Cash, 31-Dec-2020579.6 M

Grifols EV13.6 B

Grifols revenue was $5.34 b in FY, 2020

Grifols revenue breakdown by business segment: 13.4% from Transfusional Medicine, 5.2% from Bio supplies, 78.3% from Bioscience and 3.1% from Other

Grifols revenue breakdown by geographic segment: 11.5% from European Union, 5.3% from Spain, 66.5% from USA and Canada and 16.7% from Rest of the world

EUR | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Revenue | 4.3b | 4.5b | 5.1b | 5.3b |

| 7% | 4% | 14% | |

## Cost of goods sold | 2.2b | 2.4b | 2.8b | 3.1b |

## Gross profit | 2.2b | 2.0b | 2.3b | 2.3b |

| 50% | 46% | 46% | 42% |

## Sales and marketing expense | 55.1m | |||

## R&D expense | 288.3m | 240.7m | 276.0m | 294.2m |

## General and administrative expense | 860.3m | 814.8m | 942.8m | 985.6m |

## Operating expense total | 1.1b | 1.1b | 1.2b | 1.3b |

## EBIT | 1.0b | 994.1m | 1.1b | 996.1m |

| 23% | 22% | 22% | 19% |

## Pre tax profit | 695.7m | 725.8m | 817.1m | 878.6m |

## Income tax expense | 34.4m | 131.4m | 168.5m | 169.6m |

## Net Income | 661.3m | 594.4m | 648.6m | 709.0m |

## EPS | 1.0 | 0.9 | 0.9 |

EUR | H1, 2018 | H1, 2019 | H1, 2020 |
---|---|---|---|

## Revenue | 2.1b | 2.4b | 2.7b |

## Cost of goods sold | 1.1b | 1.3b | 1.6b |

## Gross profit | 1.0b | 1.1b | 1.0b |

| 47% | 46% | 39% |

## R&D expense | 112.2m | 132.6m | 142.1m |

## General and administrative expense | 387.8m | 451.0m | 484.4m |

## Operating expense total | 500.0m | 583.6m | 626.5m |

## EBIT | 506.2m | 547.9m | 421.7m |

| 24% | 23% | 16% |

## Pre tax profit | 397.3m | 368.3m | 327.1m |

## Income tax expense | 79.4m | 73.7m | 65.5m |

## Net Income | 317.9m | 294.6m | 261.7m |

## EPS | 0.5 | 0.4 | 0.3 |

EUR | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Cash | 886.5m | 1.0b | 742.0m | 579.6m |

## Accounts Receivable | 286.2m | 269.2m | 369.8m | 383.2m |

## Inventories | 1.6b | 1.9b | 2.3b | 2.0b |

## Current Assets | 2.9b | 3.5b | 5.4b | 3.2b |

## PP&E | 1.8b | 2.0b | 2.2b | 2.3b |

## Goodwill | 4.6b | 5.2b | 5.5b | 5.3b |

## Total Assets | 10.9b | 12.5b | 15.5b | 15.3b |

## Accounts Payable | 423.1m | 561.9m | 581.9m | |

## Short-term debt | 33.5m | 28.2m | 228.6m | |

## Current Liabilities | 978.0m | 1.3b | 1.4b | 1.3b |

## Long-term debt | 174.6m | 249.2m | 913.0m | 3.3b |

## Non-Current Liabilities | 6.3b | 6.5b | 7.3b | 7.2b |

## Total Debt | 208.1m | 277.4m | 1.1b | 3.3b |

## Total Liabilities | 7.3b | 7.8b | 8.7b | 8.6b |

## Common Stock | 119.6m | 119.6m | 119.6m | |

## Additional Paid-in Capital | 910.7m | 910.7m | 910.7m | |

## Retained Earnings | 662.7m | 596.6m | 625.1m | |

## Total Equity | 3.5b | 4.7b | 6.8b | 6.7b |

## Debt to Equity Ratio | 0.1 x | 0.1 x | 0.2 x | |

## Debt to Assets Ratio | 0 x | 0 x | 0.1 x | |

## Financial Leverage | 3.1 x | 2.7 x | 2.3 x | 2.3 x |

EUR | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Net Income | 661.3m | 594.4m | 648.6m | 709.0m |

## Depreciation and Amortization | 215.5m | 228.6m | 302.5m | 321.5m |

## Accounts Receivable | 80.1m | (13.1m) | (99.4m) | |

## Inventories | (165.5m) | (231.7m) | (323.7m) | |

## Accounts Payable | 22.3m | 135.3m | (44.5m) | |

## Cash From Operating Activities | 841.7m | 737.4m | 568.9m | 1.1b |

## Purchases of PP&E | (251.5m) | (232.0m) | (310.4m) | |

## Cash From Investing Activities | (2.2b) | (781.9m) | (548.8m) | (858.1m) |

## Dividends Paid | (218.3m) | (279.8m) | (238.7m) | |

## Cash From Financing Activities | 1.4b | 152.5m | (332.4m) | (354.4m) |

## Net Change in Cash | (8.5m) | 147.3m | (291.8m) | |

## Interest Paid | 207.1m | 225.1m | 236.2m | |

## Income Taxes Paid | 147.0m | 111.6m | 107.8m |

USD | FY, 2017 |
---|---|

## Revenue/Employee | 236.0k |

## Debt/Equity | 0.1 x |

## Financial Leverage | 3.1 x |

## P/E Ratio | 23.6 |

FY, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | FY, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | FY, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Countries | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |

## Plasma Collection Centers | 190 | 190 | 225 | 250 | 256 | 293 | 295 | 300 | 310 | |||

## Plasma Collection Centers (US) | 190 | 190 | 190 | 215 | 197 | |||||||

## Plasma Collection Centers (Europe) | 35 | 35 | 59 | |||||||||

## Plasma Obtained, liters | 9.3 m | 12 m | 13.5 m | |||||||||

## Hemoderivative Product Licenses | 683 | 694 | 949 | |||||||||

## Diagnostic Product Licenses | 2.32 k | 2.5 k | 3.04 k | |||||||||

## Hospital Division Product Licenses | 187 | 186 | 188 | |||||||||

## Bioscience R&D Projects (Discovery Phase) | 14 | 12 | 15 | |||||||||

## Bioscience R&D Projects (Preclinical Phase) | 12 | 12 | 19 | |||||||||

## Bioscience R&D Projects (Clinical Phase) | 26 | 28 | 21 | |||||||||

## Bioscience R&D Projects (Post Commercialization Studies Phase) | 10 | 9 | 10 | |||||||||

## Bioscience R&D Projects (Other) | 18 | 16 | 19 | |||||||||

## Patents and Patent Applications | 2.7 k | 2.97 k | 3.18 k | |||||||||

## Trademarks and Trademark Applications | 3.15 k | 3.19 k | 3.38 k |